Cargando...
The Value of EGFRvIII as the Target for Glioma Vaccines
Malignant brain tumors continue to be rapidly progressive and resistant to most treatments. Even with state-of-the-art standard of care (surgery, chemotherapy, and radiotherapy) long-term survival in the last 80 years improved from 6 to 15 months. Improved imaging has also likely contributed to prol...
Guardado en:
| Publicado en: | Am Soc Clin Oncol Educ Book |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4438702/ https://ncbi.nlm.nih.gov/pubmed/24857059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14694/EdBook_AM.2014.34.42 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|